Semaglutide, optimal therapy for type 2 diabetes with few side effects: Study
Egypt: Tirzepatide, oral, and subcutaneous (SC) semaglutide have a favorable efficacy for type 2 diabetes treatment, according to results from a meta-analysis. The adverse events were found to be comparable to placebo; however, a high rate of gastrointestinal adverse events was seen in tirzepatide, oral, and SC semaglutide groups.
The study, published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews, showed that semaglutide at 1 mg SC weekly dose and 14 mg oral dose were the favorable doses. Also, semaglutide showed more reduction in fasting blood glucose, HbA1c, and body weight versus other anti-diabetic medications.
The study was conducted by Mohamed Sayed Zaazouee, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, and colleagues with the objective to assess the safety and efficacy of semaglutide compared with placebo and other anti-hyperglycaemic agents in type 2 diabetes (T2DM).
For this purpose, the researchers searched the online databases for relevant randomized controlled trials (RCTs). To compare different doses, durations, and interventions in T2DM, a network meta-analysis was conducted. The results were presented as mean difference (MD) or relative risk (RR).
Salient findings of the study include:
- Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
- Tirzepatide showed the highest efficacy, however, it was comparable to semaglutide. SC semaglutide 1 mg once-weekly showed a higher reduction in HbA1c (MD = −1.72), and fasting blood glucose (MD = −1.93) versus placebo at 30 weeks and other time points.
- Adverse events (ADs) were comparable to placebo with oral and SC semaglutide, oral sitagliptin, SC liraglutide, and oral empagliflozin at most time points.
- SC semaglutide 0.8 mg and tirzepatide 10 mg groups had the highest gastrointestinal adverse events.
Based on the results, the researchers concluded, "semaglutide has a high probability of being the optimal therapy for type 2 diabetes."
Reference:
Zaazouee, Mohamed Sayed, et al. "Semaglutide for the Treatment of Type 2 Diabetes Mellitus: a Systematic Review and Network Meta-analysis of Safety and Efficacy Outcomes." Diabetes & Metabolic Syndrome, vol. 16, no. 6, 2022, p. 102511.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.